Novellus is an Engineered Cellular Medicine company located in Cambridge, MA. We use our patented, high efficiency platforms of mRNA-based Gene Editing and Cell Reprogramming to develop medicines for patients with devastating diseases such as AAT deficiency, Parkinson’s, Crohn’s disease, Dystrophic Epidermolysis Bullosa, etc. We engineer precision medicines for patient segments, and select from our technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. We have robust IP for mRNA-based gene editing and cell reprogramming, including over 30 granted broad patents. We are seeking strategic partners to co-develop drug candidates and to lead the clinical and commercialization efforts.